Our results are mostly consistent with those of previous studies (47–50) which have demonstrated a significant reduction of AST and ALT by microbial therapies in patients with NAFLD, though our systematic review and NMA included more up-to-date RCTs with an overall larger sample size than previous meta-analyses. This evidence concerns the gene GPT and metabolic dysfunction-associated steatotic liver disease.